Therapeutic Strategies for Hepatitis- and Other Infection-Related Immune Thrombocytopenias

Seminars in Hematology

Volumn 46, Issue SUPPL. 2, 2009, Pages

  Stasi, Roberto ^a  

^a REGINA APOSTOLORUM HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMOXICILLIN; ANTIRETROVIRUS AGENT; CLARITHROMYCIN; CORTICOSTEROID; ELTROMBOPAG; IMMUNOGLOBULIN; PREDNISOLONE; PREDNISONE; PROTON PUMP INHIBITOR; RHESUS D ANTIBODY; THROMBOPOIETIN; ZIDOVUDINE;

ARTICLE; DISEASE ASSOCIATION; HELICOBACTER PYLORI; HEPATITIS; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; PRIORITY JOURNAL;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HEPACIVIRUS; HEPATITIS C; HIV; HIV INFECTIONS; HUMANS; JAPAN; PREVALENCE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 60549086956     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2008.12.006     Document Type: Article

References (104)

1. Stasi R., Evangelista M.L., Stipa E., Buccisano F., Venditti A., and Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 99 (2008) 4-13
2. Liebman H. Other immune thrombocytopenias. Semin Hematol 44 (2007) S24-S34
3. Liebman H.A., and Stasi R. Secondary immune thrombocytopenic purpura. Curr Opin Hematol 14 (2007) 557-573
4. Blanchette V., and Bolton-Maggs P. Childhood immune thrombocytopenic purpura: diagnosis and management. Pediatr Clin North Am 55 (2008) 393-420
5. Craxi A., Laffi G., and Zignego A.L. Hepatitis C virus (HCV) infection: a systemic disease. Mol Aspects Med 29 (2008) 85-95
6. Nguyen T.T., Sedghi-Vaziri A., Wilkes L.B., Mondala T., Pockros P.J., Lindsay K.L., et al. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepat 3 (1996) 75-78
7. Seeff L.B. Natural history of chronic hepatitis C. Hepatology 36 (2002) S35-S46
8. Palekar N.A., and Harrison S.A. Extrahepatic manifestations of hepatitis C. South Med J 98 (2005) 1019-1023
9. Pyrsopoulos N.T., and Reddy K.R. Extrahepatic manifestations of chronic viral hepatitis. Curr Gastroenterol Rep 3 (2001) 71-78
10. Shepard C.W., Finelli L., and Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5 (2005) 558-567
11. Armstrong G.L., Wasley A., Simard E.P., McQuillan G.M., Kuhnert W.L., and Alter M.J. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144 (2006) 705-714
12. Sulkowski M.S. Management of the hematologic complications of hepatitis C therapy. Clin Liver Dis 9 (2005) 601-616
13. Bashour F.N., Teran J.C., and Mullen K.D. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol 95 (2000) 2936-2939
14. Rajan S.K., Espina B.M., and Liebman H.A. Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura. Br J Haematol 129 (2005) 818-824
15. Pockros P.J., Duchini A., McMillan R., Nyberg L.M., McHutchison J., and Viernes E. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol 97 (2002) 2040-2045
16. Nagamine T., Ohtuka T., Takehara K., Arai T., Takagi H., and Mori M. Thrombocytopenia associated with hepatitis C viral infection. J Hepatol 24 (1996) 135-140
17. Garcia-Suarez J., Burgaleta C., Hernanz N., Albarran F., Tobaruela P., and Alvarez-Mon M. HCV-associated thrombocytopenia: clinical characteristics and platelet response after recombinant alpha2b-interferon therapy. Br J Haematol 110 (2000) 98-103
18. Zhang L., Li H., Zhao H., Ji L., and Yang R. Hepatitis C virus-related adult chronic idiopathic thrombocytopenic purpura: experience from a single Chinese center. Eur J Haematol 70 (2003) 196-197
19. Pivetti S., Novarino A., Merico F., Bertero M.T., Brunetto M.R., Bonino F., et al. High prevalence of autoimmune phenomena in hepatitis C virus antibody positive patients with lymphoproliferative and connective tissue disorders. Br J Haematol 95 (1996) 204-211
20. Sakuraya M., Murakami H., Uchiumi H., Hatsumi N., Akiba T., Yokohama A., et al. Steroid-refractory chronic idiopathic thrombocytopenic purpura associated with hepatitis C virus infection. Eur J Haematol 68 (2002) 49-53
21. Pawlotsky J.M., Bouvier M., Fromont P., Deforges L., Duval J., Dhumeaux D., et al. Hepatitis C virus infection and autoimmune thrombocytopenic purpura. J Hepatol 23 (1995) 635-639
22. Hernandez F., Blanquer A., Linares M., Lopez A., Tarin F., and Cervero A. Autoimmune thrombocytopenia associated with hepatitis C virus infection. Acta Haematol 99 (1998) 217-220
23. Ramos-Casals M., Garcia-Carrasco M., Lopez-Medrano F., et al. Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases. Medicine (Baltimore) 82 (2003) 87-96
24. Rajan S., and Liebman H.A. Treatment of hepatitis C related thrombocytopenia with interferon alpha. Am J Hematol 68 (2001) 202-209
25. Iga D., Tomimatsu M., Endo H., Ohkawa S., and Yamada O. Improvement of thrombocytopenia with disappearance of HCV RNA in patients treated by interferon-alpha therapy: possible etiology of HCV-associated immune thrombocytopenia. Eur J Haematol 75 (2005) 417-423
26. McHutchison J.G., Dusheiko G., Shiffman M.L., et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 357 (2007) 2227-2236
27. Bussel J.B., Cheng G., Saleh M.N., et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 357 (2007) 2237-2247
28. Morris L., Distenfeld A., Amorosi E., and Karpatkin S. Autoimmune thrombocytopenic purpura in homosexual men. Ann Intern Med 96 (1982) 714-717
29. Ratnoff O.D., Menitove J.E., Aster R.H., and Lederman M.M. Coincident classic hemophilia and "idiopathic" thrombocytopenic purpura in patients under treatment with concentrates of antihemophilic factor (factor VIII). N Engl J Med 308 (1983) 439-442
30. Walsh C.M., Nardi M.A., and Karpatkin S. On the mechanism of thrombocytopenic purpura in sexually active homosexual men. N Engl J Med 311 (1984) 635-639
31. Walsh C., Krigel R., Lennette E., and Karpatkin S. Thrombocytopenia in homosexual patients. Prognosis, response to therapy, and prevalence of antibody to the retrovirus associated with the acquired immunodeficiency syndrome. Ann Intern Med 103 (1985) 542-545
32. UNAIDS. AIDS epidemic update: December 2007. http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf Accessed September 19, 2008
33. The Henry J. Kaiser Family Foundation. Fact sheet: The HIV/AIDS epidemic in the United States. HIV/AIDS policy fact sheet. http://www.kff.org/hivaids/upload/3029-08.pdf Accessed September 19, 2008
34. Kaslow R.A., Phair J.P., Friedman H.B., et al. Infection with the human immunodeficiency virus: clinical manifestations and their relationship to immune deficiency. A report from the Multicenter AIDS Cohort Study. Ann Intern Med 107 (1987) 474-480
35. Sloand E.M., Klein H.G., Banks S.M., Vareldzis B., Merritt S., and Pierce P. Epidemiology of thrombocytopenia in HIV infection. Eur J Haematol 48 (1992) 168-172
36. Rossi G., Gorla R., Stellini R., et al. Prevalence, clinical, and laboratory features of thrombocytopenia among HIV-infected individuals. AIDS Res Hum Retroviruses 6 (1990) 261-269
37. Peltier J.Y., Lambin P., Doinel C., Courouce A.M., Rouger P., and Lefrere J.J. Frequency and prognostic importance of thrombocytopenia in symptom-free HIV-infected individuals: a 5-year prospective study. AIDS 5 (1991) 381-384
38. Mientjes G.H., van Ameijden E.J., Mulder J.W., van den Hoek J.A., Coutinho R.A., and von dem Borne A.E. Prevalence of thrombocytopenia in HIV-infected and non-HIV infected drug users and homosexual men. Br J Haematol 82 (1992) 615-619
39. Sullivan P.S., Hanson D.L., Chu S.Y., Jones J.L., and Ciesielski C.A. Surveillance for thrombocytopenia in persons infected with HIV: results from the multistate Adult and Adolescent Spectrum of Disease Project. J Acquir Immune Defic Syndr Hum Retrovirol 14 (1997) 374-379
40. Burbano X., Miguez M.J., Lecusay R., et al. Thrombocytopenia in HIV-infected drug users in the HAART era. Platelets 12 (2001) 456-461
41. Landonio G., Galli M., Nosari A., et al. HIV-related severe thrombocytopenia in intravenous drug users: prevalence, response to therapy in a medium-term follow-up, and pathogenetic evaluation. AIDS 4 (1990) 29-34
42. Ciernik I.F., Cone R.W., Fehr J., and Weber R. Impaired liver function and retroviral activity are risk factors contributing to HIV-associated thrombocytopenia. Swiss HIV Cohort Study. AIDS 13 (1999) 1913-1920
43. Quan C.M., Krajden M., Grigoriew G.A., and Salit I.E. Hepatitis C virus infection in patients infected with the human immunodeficiency virus. Clin Infect Dis 17 (1993) 117-119
44. Quaranta J.F., Delaney S.R., Alleman S., Cassuto J.P., Dellamonica P., and Allain J.P. Prevalence of antibody to hepatitis C virus (HCV) in HIV-1-infected patients (nice SEROCO cohort). J Med Virol 42 (1994) 29-32
45. Berhane K., Karim R., Cohen M.H., et al. Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr 37 (2004) 1245-1252
46. Levine A.M., Karim R., Mack W., et al. Neutropenia in human immunodeficiency virus infection: data from the women's interagency HIV study. Arch Intern Med 166 (2006) 405-410
47. Karpatkin S. Autoimmune thrombocytopenias. Autoimmunity 37 (2004) 363-368
48. Ragni M.V., Bontempo F.A., Myers D.J., Kiss J.E., and Oral A. Hemorrhagic sequelae of immune thrombocytopenic purpura in human immunodeficiency virus-infected hemophiliacs. Blood 75 (1990) 1267-1272
49. Finazzi G., Mannucci P.M., Lazzarin A., et al. Low incidence of bleeding from HIV-related thrombocytopenia in drug addicts and hemophiliacs: implications for therapeutic strategies. Eur J Haematol 45 (1990) 82-85
50. Yetgin S., Demir H., Arslan D., Unal S., and Kocak N. Autoimmune thrombocytopenic purpura and Helicobacter pylori infection effectivity during childhood. Am J Hematol 78 (2005) 318
51. Murphy M.F., Metcalfe P., Waters A.H., Carne C.A., Weller I.V., Linch D.C., et al. Incidence and mechanism of neutropenia and thrombocytopenia in patients with human immunodeficiency virus infection. Br J Haematol 66 (1987) 337-340
52. Landonio G., Nosari A., Spinelli F., Vigorelli R., Caggese L., and Schlacht I. HIV-related thrombocytopenia: four different clinical subsets. Haematologica 77 (1992) 398-401
53. Servais J., Nkoghe D., Schmit J.C., et al. HIV-associated hematologic disorders are correlated with plasma viral load and improve under highly active antiretroviral therapy. J Acquir Immune Defic Syndr 28 (2001) 221-225
54. Landonio G., Cinque P., Nosari A., et al. Comparison of two dose regimens of zidovudine in an open, randomized, multicentre study for severe HIV-related thrombocytopenia. AIDS 7 (1993) 209-212
55. Oksenhendler E., Bierling P., Ferchal F., Clauvel J.P., and Seligmann M. Zidovudine for thrombocytopenic purpura related to human immunodeficiency virus (HIV) infection. Ann Intern Med 110 (1989) 365-368
56. Cinque P., Landonio G., Lazzarin A., et al. Long-term treatment with zidovudine in patients with human immunodeficiency virus (HIV)-associated thrombocytopenia: modes of response and correlation with markers of HIV replication. Eur J Haematol 50 (1993) 17-21
57. Aboulafia D.M., Bundow D., Waide S., Bennet C., and Kerr D. Initial observations on the efficacy of highly active antiretroviral therapy in the treatment of HIV-associated autoimmune thrombocytopenia. Am J Med Sci 320 (2000) 117-123
58. Carbonara S., Fiorentino G., Serio G., et al. Response of severe HIV-associated thrombocytopenia to highly active antiretroviral therapy including protease inhibitors. J Infect 42 (2001) 251-256
59. Miguez M.J., Burbano X., Archer H., and Shor-Posner G. Limited impact of highly active antiretroviral therapy in thrombocytopenia. J Acquir Immune Defic Syndr 30 (2002) 260-261
60. Schacter L.P., Rozencweig M., Beltangady M., et al. Effects of therapy with didanosine on hematologic parameters in patients with advanced human immunodeficiency virus disease. Blood 80 (1992) 2969-2976
61. Nasti G., Errante D., and Tirelli U. Successful treatment of HIV-1-related, zidovudine resistant, thrombocytopenia with didanosine. Am J Hematol 55 (1997) 118-119
62. Marroni M., Gresele P., Landonio G., et al. Interferon-alpha is effective in the treatment of HIV-1-related, severe, zidovudine-resistant thrombocytopenia. A prospective, placebo-controlled, double-blind trial. Ann Intern Med 121 (1994) 423-429
63. Northfelt D.W., Charlebois E.D., Mirda M.I., Child C., Kaplan L.D., and Abrams D.I. Continuous low-dose interferon-alpha therapy for HIV-related immune thrombocytopenic purpura. J Acquir Immune Defic Syndr Hum Retrovirol 8 (1995) 45-50
64. Oksenhendler E., Bierling P., Farcet J.P., Rabian C., Seligmann M., and Clauvel J.P. Response to therapy in 37 patients with HIV-related thrombocytopenic purpura. Br J Haematol 66 (1987) 491-495
65. Oksenhendler E., Bierling P., Chevret S., Delfraissy J.F., Laurian Y., Clauvel J.P., et al. Splenectomy is safe and effective in human immunodeficiency virus-related immune thrombocytopenia. Blood 82 (1993) 29-32
66. Scaradavou A., Woo B., Woloski B.M., Cunningham-Rundles S., Ettinger L.J., Aledort L.M., et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 89 (1997) 2689-2700
67. Najean Y., and Rain J.D. The mechanism of thrombocytopenia in patients with HIV infection. J Lab Clin Med 123 (1994) 415-420
68. Leissinger C.A., and Andes W.A. Role of splenectomy in the management of hemophilic patients with human immunodeficiency virus-associated immunopathic thrombocytopenic purpura. Am J Hematol 40 (1992) 207-209
69. Marroni M., Sinnone M.S., Landonio G., Aristei C., Boschetti E., Lazzarin A., et al. Splenic irradiation versus splenectomy for severe, refractory HIV-related thrombocytopenia: effects on platelet counts and immunological status. AIDS 14 (2000) 1664-1667
70. Andersen L.P. Colonization and infection by Helicobacter pylori in humans. Helicobacter 12 Suppl 2 (2007) 12-15
71. Suerbaum S., and Michetti P. Helicobacter pylori infection. N Engl J Med 347 (2002) 1175-1186
72. Logan R.P., and Walker M.M. ABC of the upper gastrointestinal tract: epidemiology and diagnosis of Helicobacter pylori infection. BMJ 323 (2001) 920-922
73. Graham D.Y., Kimura K., Shimoyama T., and Takemoto T. Helicobacter pylori infection in Japan: current status and future options. Eur J Gastroenterol Hepatol 6 Suppl 1 (1994) S1-S4
74. Russo A., Eboli M., Pizzetti P., et al. Determinants of Helicobacter pylori seroprevalence among Italian blood donors. Eur J Gastroenterol Hepatol 11 (1999) 867-873
75. Rajantie J., and Klemola T. Helicobacter pylori and idiopathic thrombocytopenic purpura in children. Blood 101 (2003) 1660
76. Hayashi H., Okuda M., Aoyagi N., Yoshiyama M., Miyashiro E., Kounami S., et al. Helicobacter pylori infection in children with chronic idiopathic thrombocytopenic purpura. Pediatr Int 47 (2005) 292-295
77. Jaing T.H., Yang C.P., Hung I.J., Chiu C.H., and Chang K.W. Efficacy of Helicobacter pylori eradication on platelet recovery in children with chronic idiopathic thrombocytopenic purpura. Acta Paediatr 92 (2003) 1153-1157
78. Franchini M., Cruciani M., Mengoli C., Pizzolo G., and Veneri D. Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura: a systematic review and meta-analysis. J Antimicrob Chemother 60 (2007) 237-246
79. Michel M., Cooper N., Jean C., Frissora C., and Bussel J.B. Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura?. Blood 103 (2004) 890-896
80. Stasi R., Rossi Z., Stipa E., Amadori S., Newland A.C., and Provan D. Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura. Am J Med 118 (2005) 414-419
81. Fukui O., Shimoya K., Shimizu T., Fukuda H., Wasada K., and Murata Y. Helicobacter pylori infection and platelet counts during pregnancy. Int J Gynaecol Obstet 89 (2005) 26-30
82. Fujimura K., Kuwana M., Kurata Y., et al. Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura?. Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol 81 (2005) 162-168
83. Suzuki T., Matsushima M., Masui A., et al. Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura-a randomized controlled trial. Am J Gastroenterol 100 (2005) 1265-1270
84. Inaba T., Mizuno M., Take S., et al. Eradication of Helicobacter pylori increases platelet count in patients with idiopathic thrombocytopenic purpura in Japan. Eur J Clin Invest 35 (2005) 214-219
85. Asahi A., Kuwana M., Suzuki H., Hibi T., Kawakami Y., and Ikeda Y. Effects of a Helicobacter pylori eradication regimen on anti-platelet autoantibody response in infected and uninfected patients with idiopathic thrombocytopenic purpura. Haematologica 91 (2006) 1436-1437
86. Emilia G., Luppi M., Zucchini P., et al. Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profiles. Blood 110 (2007) 3833-3841
87. Veneri D., De Matteis G., Solero P., et al. Analysis of B- and T-cell clonality and HLA class II alleles in patients with idiopathic thrombocytopenic purpura: correlation with Helicobacter pylori infection and response to eradication treatment. Platelets 16 (2005) 307-311
88. Jarque I., Andreu R., Llopis I., et al. Absence of platelet response after eradication of Helicobacter pylori infection in patients with chronic idiopathic thrombocytopenic purpura. Br J Haematol 115 (2001) 1002-1003
89. Ahn E.R., Tiede M.P., Jy W., Bidot C.J., Fontana V., and Ahn Y.S. Platelet activation in Helicobacter pylori-associated idiopathic thrombocytopenic purpura: eradication reduces platelet activation but seldom improves platelet counts. Acta Haematol 116 (2006) 19-24
90. Suvajdzic N., Stankovic B., Artiko V., et al. Helicobacter pylori eradication can induce platelet recovery in chronic idiopathic thrombocytopenic purpura. Platelets 17 (2006) 227-230
91. Estrada-Gomez R.A., Parra-Ortega I., Martinez-Barreda C., and Ruiz-Arguelles G.J. Helicobacter pylori infection and thrombocytopenia: a single-institution experience in Mexico. Rev Invest Clin 59 (2007) 112-115
92. Campuzano-Maya G. Proof of an association between Helicobacter pylori and idiopathic thrombocytopenic purpura in Latin America. Helicobacter 12 (2007) 265-273
93. Gasbarrini A., Franceschi F., Tartaglione R., Landolfi R., Pola P., and Gasbarrini G. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 352 (1998) 878
94. Kohda K., Kuga T., Kogawa K., et al. Effect of Helicobacter pylori eradication on platelet recovery in Japanese patients with chronic idiopathic thrombocytopenic purpura and secondary autoimmune thrombocytopenic purpura. Br J Haematol 118 (2002) 584-588
95. Hino M., Yamane T., Park K., et al. Platelet recovery after eradication of Helicobacter pylori in patients with idiopathic thrombocytopenic purpura. Ann Hematol 82 (2003) 30-32
96. Hashino S., Mori A., Suzuki S., et al. Platelet recovery in patients with idiopathic thrombocytopenic purpura after eradication of Helicobacter pylori. Int J Hematol 77 (2003) 188-191
97. Ando K., Shimamoto T., Tauchi T., et al. Can eradication therapy for Helicobacter pylori really improve the thrombocytopenia in idiopathic thrombocytopenic purpura?. Our experience and a literature review. Int J Hematol 77 (2003) 239-244
98. Takahashi T., Yujiri T., Shinohara K., et al. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. Br J Haematol 124 (2004) 91-96
99. Sato R., Murakami K., Watanabe K., et al. Effect of Helicobacter pylori eradication on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura. Arch Intern Med 164 (2004) 1904-1907
100. Ando T., Tsuzuki T., Mizuno T., et al. Characteristics of Helicobacter pylori-induced gastritis and the effect of H. pylori eradication in patients with chronic idiopathic thrombocytopenic purpura. Helicobacter 9 (2004) 443-452
101. Nomura S., Inami N., and Kanazawa S. The effects of Helicobacter pylori eradication on chemokine production in patients with immune thrombocytopenic purpura. Eur J Haematol 72 (2004) 304-305
102. Sayan O., Akyol Erikci A., and Ozturk A. The efficacy of Helicobacter pylori eradication in the treatment of idiopathic thrombocytopenic purpura-the first study in Turkey. Acta Haematol 116 (2006) 146-149
103. Kodama M., Kitadai Y., Ito M., et al. Immune response to CagA protein is associated with improved platelet count after Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura. Helicobacter 12 (2007) 36-42
104. Satake M., Nishikawa J., Fukagawa Y., et al. The long-term efficacy of Helicobacter pylori eradication therapy in patients with idiopathic thrombocytopenic purpura. J Gastroenterol Hepatol 22 (2007) 2233-2237